JP2019508448A - 移植片対宿主病予防の方法 - Google Patents

移植片対宿主病予防の方法 Download PDF

Info

Publication number
JP2019508448A
JP2019508448A JP2018548207A JP2018548207A JP2019508448A JP 2019508448 A JP2019508448 A JP 2019508448A JP 2018548207 A JP2018548207 A JP 2018548207A JP 2018548207 A JP2018548207 A JP 2018548207A JP 2019508448 A JP2019508448 A JP 2019508448A
Authority
JP
Japan
Prior art keywords
humanized antibody
seq
gvhd
antibody
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018548207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508448A5 (cg-RX-API-DMAC7.html
Inventor
エイ． サックス，ジェシカ
エイ． サックス，ジェシカ
イー． フォード，ジョン
イー． フォード，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2019508448A publication Critical patent/JP2019508448A/ja
Publication of JP2019508448A5 publication Critical patent/JP2019508448A5/ja
Priority to JP2022116951A priority Critical patent/JP2022163078A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018548207A 2016-03-14 2017-03-13 移植片対宿主病予防の方法 Withdrawn JP2019508448A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022116951A JP2022163078A (ja) 2016-03-14 2022-07-22 移植片対宿主病予防の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662307896P 2016-03-14 2016-03-14
US62/307,896 2016-03-14
PCT/US2017/022065 WO2017160699A2 (en) 2016-03-14 2017-03-13 Method of preventing graft versus host disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022116951A Division JP2022163078A (ja) 2016-03-14 2022-07-22 移植片対宿主病予防の方法

Publications (2)

Publication Number Publication Date
JP2019508448A true JP2019508448A (ja) 2019-03-28
JP2019508448A5 JP2019508448A5 (cg-RX-API-DMAC7.html) 2020-05-14

Family

ID=58448610

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018548207A Withdrawn JP2019508448A (ja) 2016-03-14 2017-03-13 移植片対宿主病予防の方法
JP2022116951A Pending JP2022163078A (ja) 2016-03-14 2022-07-22 移植片対宿主病予防の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022116951A Pending JP2022163078A (ja) 2016-03-14 2022-07-22 移植片対宿主病予防の方法

Country Status (13)

Country Link
US (1) US20200002422A1 (cg-RX-API-DMAC7.html)
EP (1) EP3430052A2 (cg-RX-API-DMAC7.html)
JP (2) JP2019508448A (cg-RX-API-DMAC7.html)
KR (1) KR102710759B1 (cg-RX-API-DMAC7.html)
CN (2) CN109071660A (cg-RX-API-DMAC7.html)
AU (1) AU2017234009B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018068628A2 (cg-RX-API-DMAC7.html)
CA (1) CA3017743A1 (cg-RX-API-DMAC7.html)
EA (1) EA201892071A1 (cg-RX-API-DMAC7.html)
IL (1) IL261750B2 (cg-RX-API-DMAC7.html)
MA (1) MA44408A (cg-RX-API-DMAC7.html)
MX (2) MX2018011169A (cg-RX-API-DMAC7.html)
WO (1) WO2017160699A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019512493A (ja) * 2016-03-14 2019-05-16 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 移植片対宿主病の処置または予防の方法
JP7202893B2 (ja) 2016-06-12 2023-01-12 武田薬品工業株式会社 炎症性腸疾患を治療する方法
CN111971052B (zh) * 2018-02-08 2024-07-05 小利兰.斯坦福大学托管委员会 用于异基因造血干细胞移植的方法
WO2021222239A1 (en) * 2020-04-27 2021-11-04 Children's Hospital Medical Center Precision dosing regimen
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001507210A (ja) * 1996-08-15 2001-06-05 ミレニアム ファーマシューティカルズ，インコーポレイテツド α４β７インテグリンと反応するヒト化免疫グロブリン
WO2017160700A1 (en) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0808367B1 (en) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins and uses thereof
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
EP2402309A1 (en) 2002-05-24 2012-01-04 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
CN101077867B (zh) 2002-11-18 2012-10-10 坎莫森特里克斯公司 芳基磺酰胺
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
PT1784426E (pt) 2004-09-03 2012-03-06 Genentech Inc Antagonistas humanizados anti-beta7 e suas utilizações
ES2516690T5 (es) * 2005-06-07 2017-11-21 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad de serina proteasa y su uso en métodos y composiciones para el tratamiento de rechazo de injertos y promoción de supervivencia de injertos
US20070122404A1 (en) 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
AU2009313039B2 (en) * 2008-11-07 2015-06-18 Amgen Research (Munich) Gmbh Treatment of pediatric acute lymphoblastic leukemia
MX338969B (es) * 2009-03-20 2016-05-06 Amgen Inc Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
CN103260627A (zh) * 2010-11-12 2013-08-21 真蒂奥姆有限公司 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd)
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
ES2646717T3 (es) * 2011-05-02 2017-12-15 Millennium Pharmaceuticals, Inc. Formulación para anticuerpo anti- 4 7
MX370199B (es) * 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
NZ622452A (en) * 2012-06-21 2017-10-27 Compugen Ltd Lsr antibodies, and uses thereof for treatment of cancer
BR112017003546A2 (pt) * 2014-08-21 2017-12-05 Glaxosmithkline Ip Dev Ltd amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001507210A (ja) * 1996-08-15 2001-06-05 ミレニアム ファーマシューティカルズ，インコーポレイテツド α４β７インテグリンと反応するヒト化免疫グロブリン
WO2017160700A1 (en) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"EXPRESSION OF α4β7 INTEGRIN ON MEMORY CD8+ T-CELLS IS INCREASED IN PATIENTS AT PRESENTATION OF ACU", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 18, no. 2, JPN6021013984, 2011, pages 221 - 49, ISSN: 0004884290 *
"Phase II Trial of Natalizumab (Tysabri R) Plus Prednisone for Initial Therapy of Acute Graft Versus", CLINICALTRIALS.GOV ARCHIEVE, JPN6021016210, 25 January 2016 (2016-01-25), ISSN: 0004498500 *
"Targeting Integrin a4b7-Expressing T-Cells in Steroid Refractory Intestinal GvHD", BLOOD, vol. 126, no. 23, JPN6021013982, 2015, pages 3137, ISSN: 0004884289 *

Also Published As

Publication number Publication date
EP3430052A2 (en) 2019-01-23
AU2017234009A1 (en) 2018-09-27
IL261750B2 (en) 2024-07-01
MX2025001934A (es) 2025-04-02
IL261750A (en) 2018-10-31
US20200002422A1 (en) 2020-01-02
MX2018011169A (es) 2018-12-06
IL261750B1 (en) 2024-03-01
KR102710759B1 (ko) 2024-09-25
MA44408A (fr) 2019-01-23
CN109071660A (zh) 2018-12-21
WO2017160699A2 (en) 2017-09-21
JP2022163078A (ja) 2022-10-25
EA201892071A1 (ru) 2019-03-29
AU2017234009B2 (en) 2024-06-06
CA3017743A1 (en) 2017-09-21
BR112018068628A2 (pt) 2019-07-30
KR20180120706A (ko) 2018-11-06
WO2017160699A3 (en) 2017-11-23
CN116327920A (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
JP5764524B2 (ja) 炎症性腸疾患を治療するための抗体α４β７インテグリンおよびその使用
JP5926702B2 (ja) Ｃｄ２００に対する抗体および免疫応答への使用
JP7162533B2 (ja) 炎症性腸疾患の治療を目的とする三剤併用療法
JP2022163078A (ja) 移植片対宿主病予防の方法
JP2022137024A (ja) 移植片対宿主病の処置または予防の方法
WO2021155840A1 (zh) 抗pd-1抗体在治疗恶性肿瘤中的用途
US20250122289A1 (en) Methods of treating or preventing graft versus host disease
CA3227172A1 (en) Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
EA041816B1 (ru) Способ профилактики болезни "трансплантат против хозяина"

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190611

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220722

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220801

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220802

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220809

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220912

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220913

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220930

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240827

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20241001